Johnson & Johnson Reports Record 2025 Financial Results with $94.2B Revenue and Over 90% Net Profit Growth

Jan 22, 2026 11:00 CST Updated 11:00

Johnson & Johnson

Medical Device R&D and Manufacturer

Johnson & JohnsonCloth2025 AnnualFinancial report shows its annual revenue reached 942Billion USD (+6.0%), with profits as high as268Billion USD (+90.6%）。

Among them, Johnson & Johnson's medical device businessAnnual sales reached338Billion US dollars（+6.1%），In the cardiovascular fieldShockwave products,Electrophysiology products, Abiomed products, and general surgical wound closure products are the main growth drivers.

In Johnson & Johnson's medical device business, the cardiovascular sector remains the best-performing segment (with sales reaching $8.928 billion, a year-on-year increase of 15.8%).%), while the orthopedic business performed the worst (Sales reached92.58billion dollars, a year-on-year increase of 1.1%). Ophthalmology and surgery sales were respectively54.68Billion USD (+6.3%) and101.37Billion USD (+3%).

Cardiovascular BusinessStill a rapid growth driver for Johnson & Johnson Medical Devices. Among them, IVL,Electrophysiology and cardiac interventional pumps are key to the growth of cardiovascular business.Shockwave（$11.46 billion）、Abiomed（$17.51 billion, +17.1%), Electrophysiology ($56.34 billion, +7.0%）Shockwave, due to the acquisition being completed in 2024, lacks full-year growth.But Q4 growth was the fastest in Johnson & Johnson's cardiovascular business (reaching22.9%, of which the overseas business is as high as40.7%), becoming the strongest driving force for Johnson & Johnson's cardiovascular business growth.

Electrophysiology business becomes the slowest-growing segment in Johnson & Johnson's cardiovascular field, showing signs of strain under the encirclement of giants like Boston Scientific and Medtronic. Growth is only in the single digits, and Q4 overseas growth was merely3.2%. This is unacceptable for the former king of electrophysiology.Today, Abbott,Kardium's PFA product has also been launched, and Johnson & Johnson will face greater competition this year. It is expected that Johnson & Johnson will launch a new PFA product this year to reverse its growth decline.

Fortunately,Joaquin Duato announced that, before 2030, Johnson & Johnson will launch a new PFA ablation catheter each year to compete with Boston Scientific and others.Dunli.In addition, Varipulse PFA has been used in over 40,000 patients with paroxysmal atrial fibrillation (only 10,000 patients by 2025Q2).。

And Tim SchmidReiterating that electrophysiology is a top priority for Johnson & Johnson, he reiterated his view from the previous earnings call: as competition intensifies, particularly in the PFA space,Johnson & JohnsonWill never back down easily。

"Johnson & Johnson's advantage lies in our comprehensive integrated [electrophysiology] solutions portfolio, including mapping, ablation, and cardiac imaging technologies, as well as our top-tier mapping system. With over three decades of deep [electrophysiology] expertise and a robust product pipeline, we remain steadfast and confident in our ability to continue leading globally in this vital field."

---Tim Schmid Chairman of Johnson & Johnson Global Medical Technology

Executive Evaluation

"2025 will be a leap-forward year for Johnson & Johnson, driven by the strongest portfolio and R&D pipeline in our history. Last year marked the beginning of a new era of accelerated growth powered by healthcare innovation, transforming lives across our six key therapeutic areas: oncology, immunology, neuroscience, cardiovascular, surgery, and vision. Our leadership in these critical fields continues to expand through groundbreaking science and technology.

---Joaquin Duato Johnson & JohnsonChairman and Chief Executive Officer

Johnson & Johnson Q4 Highlights

Johnson & JohnsonFDA Submission of OTTAVA Surgical RobotDe Novo Application

TRUFILL n-BCA Liquid Embolic System Receives FDA Approval for the Treatment of Symptomatic Chronic Subdural Hematoma

Future

2026 Guidance: Johnson & Johnson issued its 2026 guidance, projecting reported sales of approximately $100.5 billion (midpoint growth of 6.7%) and adjusted earnings per share of approximately $11.53 (midpoint growth of 6.9%).